|
業務類別
|
Biotechnology |
|
業務概覽
|
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity. |
| 公司地址
| 500 River Ridge Drive, Norwood, MA, USA, 02062 |
| 電話號碼
| +1 617 963-0100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.corbuspharma.com |
| 員工數量
| 28 |
| Dr. Ian Hodgson, PhD |
Chief Operating Officer |
-- |
18/03/2025 |
| Mr. Dominic Smethurst |
Chief Medical Officer |
美元 408.91K |
01/04/2025 |
| Dr. Yuval Cohen, PhD |
Chief Executive Officer and Director |
美元 621.88K |
01/04/2025 |
| Mr. Sean F. Moran, C.P.A.,M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 462.77K |
01/04/2025 |
|
|
| Dr. Yong Ben, M.D. |
Independent Director |
01/04/2025 |
| Mr. Winston Kung, M.B.A. |
Independent Director |
01/04/2025 |
| Dr. Yuval Cohen, PhD |
Chief Executive Officer and Director |
01/04/2025 |
| Dr. John K. Jenkins, M.D. |
Independent Director |
01/04/2025 |
| Ms. Rachelle S. Jacques |
Independent Director |
01/04/2025 |
| Dr. Anne Altmeyer, M.P.H.,PhD |
Independent Director |
01/04/2025 |
|
|
|
|
